Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 451

1.

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.

Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q.

Med Oncol. 2014 Mar;31(3):864. doi: 10.1007/s12032-014-0864-0. Epub 2014 Feb 12.

PMID:
24519209
2.

Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.

Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K.

Oncology. 2012;82(3):168-74. doi: 10.1159/000336078. Epub 2012 Mar 15.

PMID:
22433454
3.

Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.

Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.

J Clin Pathol. 2011 Nov;64(11):937-46. doi: 10.1136/jcp.2011.090456. Epub 2011 Jun 16.

PMID:
21680574
4.

Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.

DA Cruz Paula A, Marques O, Rosa AM, DE Fátima Faria M, Rêma A, Lopes C.

Anticancer Res. 2014 Mar;34(3):1427-34.

PMID:
24596390
5.

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2009 Jun 15;15(12):4234-41. doi: 10.1158/1078-0432.CCR-08-1479. Epub 2009 Jun 9.

6.

Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.

de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, Schmitt F.

J Clin Pathol. 2013 Mar;66(3):187-91. doi: 10.1136/jclinpath-2012-201169. Epub 2012 Oct 30.

PMID:
23112116
7.

The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.

Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M.

Pathol Res Pract. 2015 Oct;211(10):740-7. doi: 10.1016/j.prp.2015.05.011. Epub 2015 Jun 1.

PMID:
26298632
8.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
9.

Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.

Nogi H, Suzuki M, Kamio M, Kato K, Kawase K, Toriumi Y, Takeyama H, Fukushima H, Morikawa T, Uchida K.

Oncol Rep. 2011 Apr;25(4):1109-15. doi: 10.3892/or.2011.1177. Epub 2011 Feb 9.

PMID:
21308353
10.
11.

Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.

12.

Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.

Gudadze M, Kankava K, Mariamidze A, Mosidze T, Burkadze G.

Georgian Med News. 2013 Sep;(222):50-7.

PMID:
24099815
13.

Markers of tumor-initiating cells predict chemoresistance in breast cancer.

Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E.

PLoS One. 2010 Dec 20;5(12):e15630. doi: 10.1371/journal.pone.0015630.

14.

Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.

Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM.

Oncol Rep. 2012 Jan;27(1):28-38. doi: 10.3892/or.2011.1477. Epub 2011 Sep 28.

PMID:
21956537
15.

Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.

Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.

Oncology. 2011;81(5-6):336-44. doi: 10.1159/000334690. Epub 2012 Jan 11.

PMID:
22237177
16.

Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.

Chen Y, Song J, Jiang Y, Yu C, Ma Z.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11287-95. eCollection 2015.

17.

Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.

Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, Saito M.

PLoS One. 2016 Oct 21;11(10):e0165253. doi: 10.1371/journal.pone.0165253. eCollection 2016.

18.

The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.

Li W, Liu F, Lei T, Xu X, Liu B, Cui L, Wei J, Guo X, Lang R, Fan Y, Gu F, Tang P, Zhang X, Fu L.

Pathol Res Pract. 2010 Dec 15;206(12):828-34. doi: 10.1016/j.prp.2010.09.008. Epub 2010 Oct 24.

PMID:
20977976
19.

Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.

Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA.

Hum Pathol. 2013 Mar;44(3):402-11. doi: 10.1016/j.humpath.2012.06.004. Epub 2012 Oct 1.

PMID:
23036368
20.

Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.

DA Cruz Paula A, Marques O, Sampaio R, Rosa A, Garcia J, Rêma A, DE Fátima Faria M, Silva P, Vizcaíno R, Lopes C.

Anticancer Res. 2016 Sep;36(9):4629-38.

PMID:
27630305

Supplemental Content

Support Center